Immunohistochemical assessment of protein phosphorylation state: the dream and the reality
Open Access
- 22 July 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Histochemistry and Cell Biology
- Vol. 130 (3), 465-471
- https://doi.org/10.1007/s00418-008-0474-z
Abstract
The development of phosphorylation state-specific antibodies (PSSAs) in the 1980s, and their subsequent proliferation promised to enable in situ analysis of the activation states of complex intracellular signaling networks. The extent to which this promise has been fulfilled is the topic of this review. I review some applications of PSSAs primarily in the assessment of solid tumor signaling pathway activation status. PSSAs have received considerable attention for their potential to reveal cell type-specific activation status, provide added prognostic information, aid in the prediction of response to therapy, and most recently, demonstrate the efficacy of kinase-targeted chemotherapies. However, despite some successes, many studies have failed to demonstrate added value of PSSAs over general antibody immunohistochemistry. Moreover, there is still a large degree of uncertainty about the interpretation of complex and heterogeneous staining patterns in tissue samples and their relationship to the actual phosphorylation states in vivo. The next phase of translational research in applications of PSSAs will entail the hard work of antibody validation, gathering of detailed information about epitope-specific lability, and implementation of methods for standardization.Keywords
This publication has 33 references indexed in Scilit:
- Phospho-ERK Staining Is a Poor Indicator of the Mutational Status of BRAF and NRAS in Human MelanomaJournal of Investigative Dermatology, 2008
- Low phosphorylation of estrogen receptor (ER ) serine 118 and high phosphorylation of ER serine 167 improve survival in ER-positive breast cancerEndocrine-Related Cancer, 2008
- Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patientsBritish Journal of Cancer, 2008
- Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient GlioblastomaPLoS Medicine, 2008
- Buccal Mucosa Cells as In vivo Model to Evaluate Gefitinib Activity in Patients with Advanced Non–Small Cell Lung CancerClinical Cancer Research, 2007
- Prognostic Significance of Overexpression and Phosphorylation of Epidermal Growth Factor Receptor (EGFR) and the Presence of Truncated EGFRvIII in Locoregionally Advanced Breast CancerJournal of Clinical Oncology, 2007
- Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a modelLaboratory Investigation, 2007
- Lack of prognostic impact of p53 gene mutation and p53 phosphorylation at serine 15 in multimodally treated adenocarcinomas of the gastroesophageal junctionZeitschrift für Krebsforschung und Klinische Onkologie, 2006
- Her‐2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab‐based therapy in patients with metastatic breast cancerInternational Journal of Cancer, 2005
- Phosphorylation State-Specific AntibodiesThe American Journal of Pathology, 2003